-25%

est. 2Y upside i

HealthcareSeries C

Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction.

Rank

#2843

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

The candidate should view equity as a high-risk lottery ticket with negative expected value in the near term.

Last updated: July 19, 2026

Bull (15%)+59%

Colossal achieves major de-extinction milestones and secures high-value licensing deals, driving valuation to $12B (2x entry). IPO window opens. Net return 59% after 20% dilution.

Base (50%)-11%

Valuation settles near secondary market levels at $7B as company progresses towards revenue but faces delays. Net return -10.8% after dilution.

Bear (35%)-81%

Regulatory hurdles or competition slow progress; valuation compresses to $2B. Preference stack consumes large portion, net return -80.7% for common stock after dilution.

Est. time to liquidity~4.0 years

Preference Stack Risk

moderate

Funding Intensity

1040%

Total preferred liquidation preference of $620.64M represents 10.4% of secondary valuation; common stock is subordinate but still has significant equity value.

Dilution Risk

high

With very high capital intensity and no revenue, the company will likely raise additional capital within 2 years, diluting existing shareholders by an estimated 20%.

Secondary Liquidity

limited

Secondary trades at a 42% discount to the primary round, suggesting limited liquidity and downward price pressure.

Questions to Ask at the Interview

Strategic questions based on Colossal's data — designed to show you've done your homework.

  • 1

    “How will Colossal transition from scientific breakthroughs to commercial revenue?”

  • 2

    “What licensing partnerships could generate near-term revenue?”

  • 3

    “How does the employee equity pool account for founder-genius premium?”

Community

Valuation Sentiment

Our model estimates -25% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.